Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Autobio Diagnostics Co's quarterly market cap
declined
from Dec. 2025 (¥20,240 Mil) to Mar. 2026 (¥19,114 Mil) and
declined
from Mar. 2026 (¥19,114 Mil) to Jun. 2026 (¥16,583 Mil).
Autobio Diagnostics Co's annual market cap
declined
from Dec. 2023 (¥33,423 Mil) to Dec. 2024 (¥25,355 Mil) and
declined
from Dec. 2024 (¥25,355 Mil) to Dec. 2025 (¥20,240 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Autobio Diagnostics Co's Enterprise Value for Today is ¥18,090 Mil.
Autobio Diagnostics Co (SHSE:603658) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603658 vs ABT, SYK, MDT: Market Cap Comparison
For the Medical Devices subindustry, Autobio Diagnostics Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Autobio Diagnostics Co Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Autobio Diagnostics Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Autobio Diagnostics Co's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Autobio Diagnostics Co's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Autobio Diagnostics Co (SHSE:603658) has a Market Cap of ¥18,760 Mil as of Aug. 27, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Autobio Diagnostics Co and its competitors. According to the industry distribution chart, Autobio Diagnostics Co ranks #89 out of 861 companies in the Medical Devices & Instruments industry, placing it in the top 10.3%.
Is Autobio Diagnostics Co's Market Cap too high?
Autobio Diagnostics Co's current Market Cap is ¥18,760 Mil. Based on the distribution chart, Autobio Diagnostics Co ranks #89 out of 861 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Autobio Diagnostics Co has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Autobio Diagnostics Co's Market Cap compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Autobio Diagnostics Co ranks #89 out of 861 companies for Market Cap. This places Autobio Diagnostics Co in the top 10% of its industry — outperforming the majority of peers. The industry median Market Cap is 123.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 123.07, based on 861 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Autobio Diagnostics Co and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 123.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Autobio Diagnostics Co's current Market Cap is ¥18,760 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Autobio Diagnostics Co stock overvalued right now?
Based on GuruFocus' analysis, Autobio Diagnostics Co (SHSE:603658) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥40.43, compared to a current price of ¥32.83 — trading 18.8% below its estimated fair value. The current Market Cap is ¥18,760 Mil. Autobio Diagnostics Co's overall GF Score™ is 95/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Autobio Diagnostics Co (SHSE:603658), the current Market Cap is ¥18,760 Mil as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Autobio Diagnostics Co (SHSE:603658) Overvalued in 2026?
Based on GuruFocus' analysis, Autobio Diagnostics Co stock appears to be undervalued.
The current stock price of ¥32.83 is trading 18.8% below its estimated GF Value™ of ¥40.43.
GuruFocus considers Autobio Diagnostics Co to be Modestly Undervalued.
Key valuation signals for SHSE:603658:
Market Cap: ¥18,760 Mil
GF Value™: ¥40.43 vs. price of ¥32.83 (18.8% below fair value)
No single metric tells the full story. See the SHSE:603658 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Autobio Diagnostics Co Ltd is a clinical diagnostics company in China. It specializes in research and development, production, and sales of in vitro diagnostic reagents and instruments. The company's main products include immunoassay, microbiological, molecular diagnostic, and biochemical reagents, along with immunoassay, microbiological, molecular detection, and mass spectrometry instruments, as well as auxiliary testing devices.
95GF Score
Get the complete analysis for SHSE:603658
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603658 has been successfully added to your 
